Medicine and Health
By getting COVID vaccines on a regular basis, you protect your immune system against new viruses and variants
A new study suggests that getting your COVID shots on a regular basis might have benefits beyond just protecting you against the newest strains that are going around. The Washington University School of Medicine led a group of researchers who found that the vaccine makes antibodies that are effective against a wide range of variants. These antibodies might even help us build our defenses against future coronaviruses.
This is why immune imprinting is bad:
In the past four years, we’ve heard a lot about how COVID-19 is similar to and different from influenza, which is another very dangerous respiratory virus.
Since the flu is a seasonal disease (unlike COVID, as far as we know), scientists have to make changes to the flu vaccine every year based on their best guesses about which strains of the virus will be causing the most trouble. But there’s a catch. The immune system makes memory cells in response to a vaccine one year, but they don’t always make room for new cells that make antibodies the next year. This makes the immune response weaker. It’s called imprinting when this happens.
There was no information on whether imprinting could hurt the effectiveness of the COVID-19 vaccine like it could with the flu shot. Even though it doesn’t happen every year like the flu, we all know how easily this virus can change into new types, so the vaccines have been updated several times.
What the research showed
To find out more, the researchers looked at antibodies from people and mice that had been vaccinated with mRNA COVID-19. The vaccines were designed to target two different types of COVID-19: the older OG variant from the time of social distance and running out of toilet paper, and the newer Omicron variants. At some point during the pandemic, some of the people who took part had also gotten antibodies from a natural COVID infection.
There was evidence of imprinting from the first vaccine, but it didn’t seem to be having the bad effects that it can have with flu shots. Not many of the antibodies that were found were specific to either original COVID or Omicron. Instead, most of them were cross-reactive, which means they recognized both types of the virus.
The antibodies were then put to the test against a group of different coronaviruses. Two types of SARS-CoV-2 came from different Omicron lineages. These included a pangolin coronavirus, the SARS virus from the 2002–2003 epidemic, and the virus that caused Middle Eastern Respiratory Syndrome (MERS). The antibodies were able to stop all of these viruses except for MERS, which is more different from the others in terms of how it evolved.
The combination of the different vaccines was what the scientists found to be the key to this cross-reactivity. When people were only vaccinated against the original COVID variant and not given an Omicron booster, they did not make the same range of antibodies. This means that staying up-to-date on the newest variants and regularly immunizing more people against them could have even bigger benefits than just keeping COVID away.
When COVID hit, we had to start over. Most people had never seen or heard of a virus like this before, so there wasn’t a level of immunity in the population to help protect us. If people keep getting vaccinated against COVID, this study raises the interesting possibility that things would be very different if a new coronavirus showed up.
“We don’t know for sure if getting a new COVID-19 vaccine every year would protect people against new coronaviruses, but it seems likely,” said Michael Diamond, a senior study author. “Based on these results, it looks like these cross-reactive antibodies may help protect against a pandemic caused by a related coronavirus if they don’t go away quickly. To be sure, we would have to keep an eye on their levels over time.”
What’s new with vaccines and the different types of FLiRT?
That all sounds pretty good, though. Just recently, there was news about a whole new set of COVID variants. How are our efforts to vaccinate people right now?
The FLiRT variants are the most recent ones to receive a lot of calls around the world. One in particular, KP.2, has recently passed JN.1 as the most common virus in the US, causing the second most infections.
Some people believe that KP.2’s mutations may have protected it from infections and vaccines in the past. However, this new research backs up what many health experts have already said: all the antibodies you’ve made in the past will still be helping to protect you.
Staying healthy is important, though, so if you can get an up-to-date shot where you live (especially if it’s been a while since your last one), you might want to think about it, or you could wait until the next round of updates. Not long ago, epidemiologist Adrian Esterman told Newsweek, “There will be a new vaccine available around September that will give much better protection. It will be based on either JN.1 or one of the FLiRT subvariants.”
The AstraZeneca vaccine was taken off the global market not long ago, which also changed the vaccine landscape. When new types of viruses came out, AstraZeneca did not change the formula for their vaccine, Vaxzevria. This is different from some other companies that make mRNA vaccines, for example.
Without these updates, Vaxzevria probably isn’t working as well as it used to, and because of a drop in demand, AstraZeneca is said to have decided to stop making it for business reasons. When it was first made, it was an important part of the global pandemic response. But now that there are so many other options—something we could only dream of in the darkest days of 2020—it seems like it’s done its job.
But if you were one of the millions of people who got this vaccine, this new antibody research should give you confidence that the good effects could last for a long time after the vaccine is no longer available. This is because of any booster shots you have had or will continue to get.
The study was written up in Nature.
Medicine and Health
A recently identified strain of deadly fungus poses a significant risk to public health
Researchers have recently discovered a new group of Candida auris, a potentially dangerous pathogen. The finding increases the total number of identified clades of the fungus, which is a newly emerging superbug resistant to multiple drugs, to six.
Candida auris is a strain of yeast that has the potential to cause serious illness and is frequently impervious to antifungal drugs. While individuals who are in good health generally do not fall ill, the transmission of the disease is highly prevalent within medical institutions and poses a significant risk to individuals with compromised immune systems. The yeast can induce a variety of conditions ranging from superficial infections of the skin to more severe and life-threatening illnesses, such as bloodstream infections. Due to its high level of resistance to multiple drugs, treating it can be challenging, and in some cases, even impossible.
The authors state that the pathogen is a significant global public health threat due to its widespread distribution, resistance to multiple drugs, high ability to spread, tendency to cause outbreaks, and high mortality rate. Although infections are still relatively uncommon, there has been a significant increase in cases in recent years.
Previously, the fungus had been categorized into five distinct clades, each located in different geographic regions: South Asia, East Asia, Africa, South America, and Iran.
In April 2023, doctors from the Singapore General Hospital identified a patient carrying a unique strain of C. auris as part of a routine screening program, adding it as the most recent clade to be discovered. Typically, these cases arise from individuals who have recently traveled, but this particular patient had not traveled outside the country for a period of two years, which raised some concerns.
Upon conducting a genetic analysis of the strain, the researchers determined that it did not align with any of the five known clades of the fungus. Therefore, it can be concluded that the strain belongs to a previously unidentified, sixth clade. Subsequently, they conducted tests on strains obtained from previous patients and identified two additional isolates of this particular group of C. auris in Singapore, as well as another isolate in Bangladesh.
The extent of the new clade’s prevalence and its potential to cause invasive infections and outbreaks remains uncertain at present. However, the researchers emphasize the importance of promptly identifying and controlling it in order to safeguard patient well-being.
“The ramifications of this breakthrough transcend the confines of the laboratory.” “Given the recent discovery of the sixth Candida auris clade, it is imperative to enhance surveillance capability or create new methods to strengthen existing surveillance strategies. This will enable health care facilities to closely monitor its emergence and effectively control its spread,” stated Dr. Karrie Ko, co-first author of the study.
Fortunately, the cases described in the study remained vulnerable to all antifungals that were tested. This should alleviate concerns about a pandemic similar to the one depicted in The Last Of Us. However, it is evident that the threat of C. auris is persistent. Therefore, additional efforts are required to identify new strains, monitor their spread, and control any negative clinical consequences.
The research is published in The Lancet Microbe journal.
Medicine and Health
What makes your chest hurt when something makes you jump?
Have you ever been scared so badly that you grabbed your chest? You feel like someone or something just zapped you behind the sternum. As you rest, you lean against the wall and think about why your friend is such a jerk and why you can feel it in your chest whenever you get scared.
People often use words like “heart-stopping” when they write fiction about fear, but the science of fear tells us that this isn’t what’s happening because it wouldn’t make sense. Our bodies are getting ready to deal with an impending threat when we’re scared, and going into cardiac arrest wouldn’t help us get very far if a lion was after us.
What do we do when we’re scared?
The sympathetic nervous system is what gets you excited when something makes you jump. It’s a tool inside our bodies that releases hormones and changes the way our bodies work to get us ready for the fight-or-flight response.
One important part is adrenaline, which is also known as epinephrine. The adrenal glands squeeze it out into the blood. The heart starts beating faster, sending more blood to your muscles and organs right away. Because they need all the oxygen they can get if they want to get away from a dangerous animal.
How do you feel when you go for a run?
Anyone who has ever used an EpiPen knows how bad it is to feel a sudden rush of adrenaline. It’s a stress hormone that makes you feel nervous and anxious, like you would before doing a bungee jump. Getting a rush when you think about a traumatic event from the past can be a sign of PTSD.
A medicine called adrenaline is used because it can help people who are having a medical emergency. If you have anaphylaxis from an allergen like peanuts, this can help because it can open your airway. Because it changes the strength and speed of heartbeats, it is also sometimes used to help people who are having a cardiac arrest.
When your adrenaline level goes up quickly, you may feel shaky, your heart beat quickly, and your chest get tight. When you add in the fact that you’re more alert, you become very aware of the changes in your body. This is especially clear when you’re not in danger, like when your partner surprised you at home when you thought you were alone.
When you’re scared, your sympathetic nervous system usually kicks in, which is normal. But, some heart conditions can get worse when you’re scared. Should anyone be having chest pain or ongoing discomfort, they should see a doctor. In the end, it is possible to be so scared that you die.
This article is not meant to be a replacement for medical advice, diagnosis, or treatment from a trained professional. If you have questions about a medical condition, you should always talk to a qualified health professional.
Medicine and Health
The Lacks family is suing again over her “stolen” cells
The family of Henrietta Lacks has filed a new lawsuit against two sizable drug companies for using her genetic material without her consent.
In the US District Court for the District of Maryland, Lacks’ living relatives are suing Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc., Viatris, Inc., and its subsidiary, Mylan Pharmaceuticals. They say the companies have used the “stolen” HeLa cell line to make hundreds of patents and have made a lot of money from it.
The suit wants the money made from using these cells to be “rightfully transferred” to Henrietta Lacks’s estate.
Novartis and Viatris chose to sell Henrietta Lacks’ living genetic material. Lacks was a black grandmother, community leader, and woman whose doctors took her tissue without her knowledge or permission, according to Chris Ayers, an attorney at Seeger Weiss LLP who is representing the Lacks family.
Ayers added, “We will keep looking for justice for Mrs. Lacks and her family.”
Henrietta Lacks died on October 4, 1951, from cervical cancer. She was 31 years old. Some of her cells are still alive today. A doctor at Johns Hopkins Hospital took a sample of her cervical cells without her knowledge just before she died. They were doing a cancer check. It was seen that her cells kept multiplying quickly, even after most of the cells in other samples would have died without their host.
Because scientists saw the potential, they found that these cells could be a cheap and easy way to help researchers do more research. The “HeLa immortal cell line” is what scientists call these cells, and they are very useful for biomedical research.
Over 75,000 scientific studies around the world have used these cells, which amount to about 55 million tons. They have been very important in making progress in areas like polio vaccines, cancer treatments, HIV/AIDS treatments, and much more.
All of this was done, though, without Lacks’ knowledge or permission. For many years, her family also didn’t know that the cells were being used for business.
Selling HeLa cells for money brings up important issues in medical ethics and genetics. As a black woman living in America in the 1950s, Lacks’ case shows how medical racism still affects minorities who aren’t getting enough help.
Even though a lot of people know about these problems, HeLa cells are still used in medical research for profit, which makes some companies a lot of money.
“Now that everyone knows Henrietta Lacks’ story, it’s shocking, but not surprising, that drug companies like Novartis and Viatris are still making money off of the deeply unethical origins of HeLa cells and the disturbing history of medical racism,” said Chris Seeger, another lawyer for the family.
A historic deal was made by Lacks’ family in 2023 after they sued Thermo Fisher Scientific, Inc., another biotech company, in the US District Court for the District of Baltimore. During that time, the lawyers said that the settlement was only the beginning and that there could be many more lawsuits about the use of HeLa cells.
- Gadgets10 years ago
Why the Nexus 7 is still a good tablet in 2015
- Mobile Devices10 years ago
Samsung Galaxy Note 4 vs Galaxy Note 5: is there room for improvement?
- Editorials10 years ago
Samsung Galaxy Note 4 – How bad updates prevent people from enjoying their phones
- Mobile Devices9 years ago
Nexus 5 2015 and Android M born to be together
- Gaming10 years ago
New Teaser For Five Nights At Freddy’s 4
- Mobile Devices9 years ago
Google not releasing Android M to Nexus 7
- Gadgets10 years ago
Moto G Android 5.0.2 Lollipop still has a memory leak bug
- Mobile Devices9 years ago
Nexus 7 2015: Huawei and Google changing the game